New report from PatientView: DRUG PRICING & MARKET ACCESS IN TIMES OF AUSTERITY
Please click on SAMPLE PAGES to view contents and example pages of the report
A new report by PatientView finds that …
“Having a fair pricing policy” stands out as an important strategy that 600 respondent patient groups recommend pharmaceutical companies should adopt to enhance corporate reputation. The majority of the respondent patient groups believe that few companies have, as yet, been able to attain such a goal. Analysis included for Canada, France, Germany, Italy, Spain, UK, and the USA.
Four senior patient advocates discuss market access in times of austerity
- Jay Iyer, Head of Research at the US-based Access to Medicine Foundation, discusses how pharma companies can improve their reputation by adopting simple policies which support the provision of medicines to poor people in developing nations, such as donations and fair pricing policies.
- Kathi Apostolidis, Greek cancer patient advocate, describes the appalling situation of healthcare in Greece. Patient groups are having to collect unused medicines to support the country’s new volunteer social clinics. She calls on pharma to provide greater support to these clinics, as well as adopt more pragmatic pricing policies.
- Albert Jovell, President of the Foro Español de Pacientes, talks about the impact of austerity on Spanish patients, specifically the effect of the country’s controversial medicines co-payment system on people with low incomes. New legislation may exacerbate inequities in medicines access across Spain.
- Andrew Wilson, Chief Executive of the Rarer Cancers Foundation, is alarmed by the possible ending of drug reimbursement provided to date by the Cancer Drugs Fund when value-based pricing is adopted in the UK in 2014. He foresees many problems ahead for pharma and the NHS.
The collapse of social healthcare, and the need for a more empathic way for pharma to do business
The healthcare situation in Greece, in Spain, in developing nations, and, to some extent, in the UK, could be emblamatic of the degradation of the developed world’s healthcare systems so long predicted by economists and policymakers. What this report makes clear is that pharma needs to develop an appropriate response to growing health inequities, poverty, and the chronically ill—responses which need to include new strategies toward pricing and the marketing of their products.
For more information about this report …
Please contact Dr Alexandra Wyke or Clive Nead at firstname.lastname@example.org